Page last updated: 2024-11-12

cs 0777

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

CS 0777: a sphingosine-1-phosphate receptor modulator [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	11371290
CHEMBL ID	1951587
SCHEMBL ID	1454408
MeSH ID	M0569941

Synonyms (14)

Synonym
SCHEMBL1454408
cs-0777 ,
cs 0777
1192731-63-7
CHEMBL1951587
(2r)-2-amino-2-methyl-4-{1-methyl-5-[4-(4-methylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol
YXEQXPNSBUIRDZ-OAQYLSRUSA-N
kch74qg79a ,
unii-kch74qg79a
827344-05-8
1-butanone, 1-(5-((3r)-3-amino-4-hydroxy-3-methylbutyl)-1-methyl-1h-pyrrol-2-yl)-4-(4-methylphenyl)-
Q27282183
(r)-1-(5-(3-amino-4-hydroxy-3-methylbutyl)-1-methyl-1h-pyrrol-2-yl)-4-(p-tolyl)butan-1-one
STARBLD0033600

Research Excerpts

Pharmacokinetics

Excerpt	Reference	Relevance
"Pharmacokinetic (PK) and pharmacodynamic (PD) modeling was conducted for the reduction of peripheral lymphocytes after oral administration of CS-0777 to healthy rats, monkeys and experimental autoimmune encephalomyelitis (EAE) induced rats."	( Evaluation of species difference in peripheral lymphocyte reduction effect of CS-0777, a sphingosine 1-phosphate receptor modulator, based on a pharmacokinetic/pharmacodynamic model analysis. Doi-Komuro, H; Goto, M; Inaba, SI; Inoue, R; Izumi, T; Kagari, T; Oshima, K; Shimozato, T; Tanaka, H; Tanaka-Takanaka, K; Tomisato, W; Yuita, H, 2016)	0.43

Bioavailability

Excerpt	Reference	Relevance
" After oral administration of [14C]CS-0777, CS-0777 was well absorbed in rats and monkeys with total recoveries of over 90% of the dose, majorly in feces."	( Pharmacokinetics and disposition of CS-0777, a sphingosine 1-phosphate receptor modulator, in rats and monkeys. Goto, M; Ikeda, T; Inaba, S; Iwabuchi, H; Izumi, T; Takahashi, M; Tanaka, H, 2015)	0.42

Dosage Studied

Excerpt	Relevance	Reference
" Subsequently, simulations were utilized to design a multiple ascending dose study with adaptive dosing regimens that would meet targeted pharmacodynamic (PD) response thresholds (eg, minimum 40% reduction in lymphocytes) while maintaining CD4 counts above a reasonable safety threshold."	( Use of an exposure-response model to aid early drug development of an oral sphingosine 1-phosphate receptor modulator. Carrothers, TJ; Inaba, S; Moberly, JB; Rohatagi, S; Shimozato, T; Truitt, KE; Zahir, H, 2009)	0.35

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (33)

Assay ID	Title	Year	Journal	Article
AID645304	Oral bioavailability in Sprague-Dawley rat assessed as CS-0777-phosphate at 0.1 mg/kg	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.
AID645096	Lymphopenic activity in Lewis rat assessed as recovery of blood lymphocytes at 1 mg/kg, po after 48 hrs relative to control	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.
AID645100	Reduction of cumulative disease score in Lewis rat EAE model at 1 mg/kg, po administered daily for 20 days measured after 8 to 21 days relative to control	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.
AID645104	Tmax in Sprague-Dawley rat at 1 mg/kg, po	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.
AID1054249	Half life of the compound	2013	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23	Modulators of the Sphingosine 1-phosphate receptor 1.
AID645114	Volume of distribution at steady state in Sprague-Dawley rat at 1 mg/kg, iv	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.
AID645112	Total body clearance in Sprague-Dawley rat at 1 mg/kg, iv	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.
AID645101	Cmax in Sprague-Dawley rat at 0.1 mg/kg, po	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.
AID645107	AUC (0 to infinity) in Sprague-Dawley rat at 0.1 mg/kg, po	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.
AID645102	Cmax in Sprague-Dawley rat at 1 mg/kg, po	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.
AID645299	Tmax in Sprague-Dawley rat assessed as CS-0777-phosphate at 1 mg/kg, po	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.
AID645296	Cmax in Sprague-Dawley rat assessed as CS-0777-phosphate at 0.1 mg/kg, po	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.
AID645303	AUC (0 to infinity) in Sprague-Dawley rat assessed as CS-0777-phosphate at 1 mg/kg, po	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.
AID645298	Tmax in Sprague-Dawley rat assessed as CS-0777-phosphate at 0.1 mg/kg, po	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.
AID645300	Half life in Sprague-Dawley rat assessed as CS-0777-phosphate at 0.1 mg/kg, po	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.
AID645098	Lymphopenic activity in Lewis rat assessed as recovery in blood lymphocyte counts at 1 mg/kg, po after 5 days	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.
AID645095	Lymphopenic activity in Lewis rat assessed as recovery of blood lymphocytes at 0.1 mg/kg, po after 48 hrs relative to control	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.
AID645105	Half life in Sprague-Dawley rat at 0.1 mg/kg, po	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.
AID645110	Oral bioavailability in Sprague-Dawley rat at 1 mg/kg	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.
AID645099	Reduction of cumulative disease score in Lewis rat EAE model at 0.1 mg/kg, po administered daily for 20 days measured after 8 to 21 days relative to control	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.
AID645093	Lymphopenic activity in Lewis rat assessed as reduction in blood lymphocyte counts at 0.1 mg/kg, po after 12 hrs relative to control	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.
AID645113	Volume of distribution at steady state in Sprague-Dawley rat at 0.1 mg/kg, iv	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.
AID645111	Total body clearance in Sprague-Dawley rat at 0.1 mg/kg, iv	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.
AID645305	Oral bioavailability in Sprague-Dawley rat assessed as CS-0777-phosphate at 1 mg/kg	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.
AID645297	Cmax in Sprague-Dawley rat assessed as CS-0777-phosphate at 1 mg/kg, po	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.
AID645302	AUC (0 to infinity) in Sprague-Dawley rat assessed as CS-0777-phosphate at 0.1 mg/kg, po	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.
AID645108	AUC (0 to infinity) in Sprague-Dawley rat at 1 mg/kg, po	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.
AID645109	Oral bioavailability in Sprague-Dawley rat at 0.1 mg/kg	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.
AID645106	Half life in Sprague-Dawley rat at 1 mg/kg, po	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.
AID645097	Lymphopenic activity in Lewis rat assessed as recovery in blood lymphocyte counts at 0.1 mg/kg, po after 5 days	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.
AID645103	Tmax in Sprague-Dawley rat at 0.1 mg/kg, po	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.
AID645094	Lymphopenic activity in Lewis rat assessed as reduction in blood lymphocyte counts at 1 mg/kg, po after 12 hrs relative to control	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.
AID645301	Half life in Sprague-Dawley rat assessed as CS-0777-phosphate at 1 mg/kg, po	2011	ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5	Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (10.00)	29.6817
2010's	9 (90.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	18.24 (24.57)
Research Supply Index	2.56 (2.92)
Research Growth Index	5.62 (4.65)
Search Engine Demand Index	10.37 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (18.24)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	2 (20.00%)	5.53%
Reviews	1 (10.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	7 (70.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	5.54	8	2	pyrrole; secondary amine
levamisole Levamisole: An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6). levamisole : A 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole that has S configuration. It is used (generally as the monohydrochloride salt) to treat parasitic worm infections in pigs, sheep and cattle and was formerly used in humans as an adjuvant to chemotherapy for the treatment of various cancers. It is also widely used as an adulterant to coccaine.	2.17	1	0	6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole	antinematodal drug; antirheumatic drug; EC 3.1.3.1 (alkaline phosphatase) inhibitor; immunological adjuvant; immunomodulator
fingolimod hydrochloride Fingolimod Hydrochloride: A sphingosine-derivative and IMMUNOSUPPRESSIVE AGENT that blocks the migration and homing of LYMPHOCYTES to the CENTRAL NERVOUS SYSTEM through its action on SPHINGOSINE 1-PHOSPHATE RECEPTORS. It is used in the treatment of MULTIPLE SCLEROSIS.. fingolimod hydrochloride : The hydrochloride salt of 2-amino-2-[2-(4-octylphenyl) ethyl]-1,3-propanediol (fingolimod).	2.08	1	0	hydrochloride	immunosuppressive agent; prodrug; sphingosine-1-phosphate receptor agonist
fingolimod fingolimod : An aminodiol that consists of propane-1,3-diol having amino and 2-(4-octylphenyl)ethyl substituents at the 2-position. It is a sphingosine 1-phosphate receptor modulator used for the treatment of relapsing-remitting multiple sclerosis. A prodrug, fingolimod is phosphorylated by sphingosine kinase to active metabolite fingolimod-phosphate, a structural analogue of sphingosine 1-phosphate.	3.18	1	0	aminodiol; primary amino compound	antineoplastic agent; CB1 receptor antagonist; immunosuppressive agent; prodrug; sphingosine-1-phosphate receptor agonist
D-fructopyranose [no description available]	2.51	2	0	cyclic hemiketal; D-fructose; fructopyranose	sweetening agent
sphingosine sphing-4-enine : A sphingenine in which the C=C double bond is located at the 4-position.. sphingenine : A 2-aminooctadecene-1,3-diol having (2S,3R)-configuration.. sphingoid : Sphinganine, its homologs and stereoisomers, and the hydroxy and unsaturated derivatives of these compounds.. 2-aminooctadec-4-ene-1,3-diol : A 2-aminooctadecene-1,3-diol having its double bond at position 4.	4.14	3	1	sphing-4-enine	human metabolite; mouse metabolite
sphingosine 1-phosphate sphingosine 1-phosphate: RN given refers to (R-(R,S-(E)))-isomer; RN for cpd without isomeric designation not available 8/89. sphingosine 1-phosphate : A phosphosphingolipid that consists of sphingosine having a phospho group attached at position 1	3.85	2	1	sphingoid 1-phosphate	mouse metabolite; signalling molecule; sphingosine-1-phosphate receptor agonist; T-cell proliferation inhibitor; vasodilator agent
1-deoxy-1-morpholinofructose [no description available]	2.51	2	0
ponesimod ponesimod: structure in first source	3.18	1	0
fty 720p [no description available]	2.06	1	0
siponimod siponimod: S1P receptor modulator	3.18	1	0

Condition	Relationship Strength	Studies
Lymphocytopenia [description not available]	2.07	1
MS (Multiple Sclerosis) [description not available]	2.07	1
Lymphopenia Reduction in the number of lymphocytes.	2.07	1
Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)	2.07	1

chemdatabank.com